Trials / Recruiting
RecruitingNCT06551116
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | CE-10-IVD | Leftover tumor tissue from a routine biopsy will be sent for analysis. |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2029-09-01
- Completion
- 2029-09-01
- First posted
- 2024-08-13
- Last updated
- 2026-04-07
Locations
37 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06551116. Inclusion in this directory is not an endorsement.